Blog Archive
-
▼
2008
(233)
-
▼
March
(40)
- Medtronic : Announces Sales Milestone of One Milli...
- AgaMatrix : WaveSense Europe Launches Jazz Glucose...
- Boston Scientific : TAXUS Express Stent Shows Simi...
- SemBioSys : toxicology study for safflower-produce...
- Keryx Biopharmaceuticals : Termination of SUN-MACR...
- Atherotech 's VAP Test Helps Researchers Uncover B...
- Generex Biotechnology : Its Protocol for Metcontr...
- Echo Therapeutics : Positive Results from Symphony...
- Oramed Pharmaceuticals : Phase 2A Trials of Its Or...
- MacroChem, Pexiganan Phase 3 Study Results for Top...
- MannKind : Response to Recent Market Events
- Generex Oral-lyn, another regulatory approval to c...
- Metabolon and EGIR, Partnership to Accelerate Pre-...
- Mercury Therapeutics : series of indirect AMPK act...
- Sirtris' SIRT1 Activators; Patent Covers First NCE...
- DiObex and Camurus , Agreement for the Development...
- Lilly and Transition Therapeutics, Licensing and C...
- Synvista Therapeutics, Newly Published Data Demons...
- PPD, Takeda's NDA Filing of Alogliptin with U.S. F...
- Alizyme's cetilistat Phase III development program...
- Axis-Shield, HbA1c Test on Abbott's AXSYM Analyser
- Marcadia Biotech and Merck, strategic collaboration
- OSI Pharmaceuticals : the Prior Revocation of Its ...
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Diamyd Medical, Authorization to Begin Phase III S...
- Sernova, First Regulatory Step Towards Clinical Tr...
- Cannasat Therapeutics, Update on Patent Applicatio...
- Living Cell Technologies' DiabeCell Clinical Trial...
- Nitric BioTherapeutics, Phase II Clinical Trial fo...
- Oramed Pharmaceuticalsals, Phase 1B Clinical Trial...
- Abbott's FreeStyle Navigator Continuous Glucose Mo...
- Elixir Pharmaceuticals, new data on the role of gh...
- Akesis Pharmaceuticals, First Patient in Phase IIa...
- Oculus Innovative Sciences, Phase II Data with Mic...
- Alkermes, Eli Lilly, Termination of AIR (Inhaled) ...
- PLC Systems' RenalGuard Therapy and RenalGuard Sys...
- Novocell, Successful Use of Stem Cells to Generate...
- Novartis Eucreas combination of Galvus® and metfor...
- Johnson & Johnson Diabetes Institute, New Center T...
- Metabasis Therapeutics, Proof-of-Concept Clinical ...
-
▼
March
(40)
Thursday, March 13, 2008
Abbott's FreeStyle Navigator Continuous Glucose Monitoring System : FDA approved
March 13, 2008 - The Food and Drug Administration (FDA) has approved the FreeStyle Navigator® Continuous Glucose Monitoring System in the United States for people with diabetes. Designed to discretely and continuously measure glucose levels through a sensor in the back of the upper arm or abdomen, Abbott's FreeStyle Navigator system provides minute-by-minute information about which way and how quickly blood sugar levels are changing. This information can lead to proactive adjustments that can result in tighter glucose ranges. Before adjusting therapy for diabetes management based on the results and alarms from the FreeStyle Navigator system, traditional blood glucose tests must be performed... Abbott's Press Release -